Discrepancy in virological and biochemistry response of patients with chronic hepatitis HCV positive on treatment with PEG-IFN plus ribavirin

Journal of Biological Regulators and Homeostatic Agents

Volumn 17, Issue 2, 2003, Pages 205-206

  Marino, N ^a   Blanc, P L ^a   Ble C ^a   Pierotti, P ^a   Mazzotta, F ^a  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

HCV hepatitis; HCV therapy; PEG IFN

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; CHRONIC HEPATITIS; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; TREATMENT OUTCOME; TREATMENT PLANNING; VIROLOGY;

HEPATITIS C VIRUS; PUFFINUS AURICULARIS; RNA VIRUSES;

EID: 0141727874     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Trepo C, Lindsay K, Niederau C, et al. Pegylated interferon alfa-2b (PEG-Intron) monotheraphy is superior to interferon alfa-2b (Intron A) for the treatment of chronic hepatitis C. Program and Abstracts of the 35th Annual Meeting of the European Association for the Study of the Liver; April 30-May 3, 2000; Rotterdam, The Netherlands. Abstract GS2/07.
2. Fried MW, Schiffman ML, Reddy RK, et al. Pegylated (40kDa) interferon alfa-2a (Pegasys®) in combination with ribavirin: efficacy and safety results from a phase III randomized, actively-controlled, multicentre study. DDW 2001, Atlanta, USA.
3. Manns MP, McHutchison JG, Gordon SC, et al and International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
4. McHutchison JG, Fried MW. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis 2003; 7: 149-61.
5. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
6. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.